首页 | 本学科首页   官方微博 | 高级检索  
     


Pathogenic Mitochondrial tRNA Point Mutations: Nine Novel Mutations Affirm Their Importance as a Cause of Mitochondrial Disease
Authors:Emma L. Blakely  John W. Yarham  Charlotte L. Alston  Kate Craig  Joanna Poulton  Charlotte Brierley  Soo‐Mi Park  Andrew Dean  John H. Xuereb  Kirstie N. Anderson  Alistair Compston  Chris Allen  Saba Sharif  Peter Enevoldson  Martin Wilson  Simon R. Hammans  Douglass M. Turnbull  Robert McFarland  Robert W. Taylor
Affiliation:1. Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, , Newcastle upon Tyne, UK;2. Nuffield Department of Obstetrics and Gynaecology, University of Oxford, , Oxford, UK;3. Department of Neurology, The West Suffolk Hospital, Bury St Edmunds, , Suffolk, UK;4. Department of Clinical Genetics, East Anglian Medical Genetics Service, Addenbrooke's Hospital, , Cambridge, UK;5. Department of Pathology, University of Cambridge, , Cambridge, UK;6. Department of Neurology, Royal Victoria Infirmary, , Newcastle upon Tyne, UK;7. Department of Clinical Neurosciences, University of Cambridge, , Cambridge, UK;8. Department of Neurology, Addenbrooke's Hospital, , Cambridge, UK;9. West Midlands Regional Clinical Genetics Unit, Birmingham Women's NHS Foundation Trust, , Birmingham, UK;10. The Walton Centre NHS Foundation Trust, , Liverpool, UK;11. Wessex Neurological Centre, University Hospitals Southampton, , Southampton, UK
Abstract:Mutations in the mitochondrial genome, and in particular the mt‐tRNAs, are an important cause of human disease. Accurate classification of the pathogenicity of novel variants is vital to allow accurate genetic counseling for patients and their families. The use of weighted criteria based on functional studies—outlined in a validated pathogenicity scoring system—is therefore invaluable in determining whether novel or rare mt‐tRNA variants are pathogenic. Here, we describe the identification of nine novel mt‐tRNA variants in nine families, in which the probands presented with a diverse range of clinical phenotypes including mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes, isolated progressive external ophthalmoplegia, epilepsy, deafness and diabetes. Each of the variants identified (m.4289T>C, MT‐TI; m.5541C>T, MT‐TW; m.5690A>G, MT‐TN; m.7451A>T, MT‐TS1; m.7554G>A, MT‐TD; m.8304G>A, MT‐TK; m.12206C>T, MT‐TH; m.12317T>C, MT‐TL2; m.16023G>A, MT‐TP) was present in a different tRNA, with evidence in support of pathogenicity, and where possible, details of mutation transmission documented. Through the application of the pathogenicity scoring system, we have classified six of these variants as “definitely pathogenic” mutations (m.5541C>T, m.5690A>G, m.7451A>T, m.12206C>T, m.12317T>C, and m.16023G>A), whereas the remaining three currently lack sufficient evidence and are therefore classed as ‘possibly pathogenic’ (m.4289T>C, m.7554G>A, and m.8304G>A).
Keywords:mitochondrial tRNA  single‐fiber studies  mitochondrial disease  segregation
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号